The effect of ERCC1 and ERCC2 gene polymorphysims on response to cisplatin based therapy in osteosarcoma patients

BMC Medical Genetics

Table 6 Association between Alleles and median EFS rate in osteosarcoma patients treated with cisplatin combinations

Alleles	Median EFS survival rate in years	Log rank
ERCC1 118 C allele	CC + CT 1.70	0.549
ERCC1 118 C allele	TT 1.73	0.549
ERCC1 118 T allele	TT + CT 1.49	0.647
ERCC1 118 T allele	CC 2.29	0.647
ERCC1 8092 C allele	CC + CA 2.04	0.006
ERCC1 8092 C allele	AA 0.24	0.006
ERCC1 8092 A allele	AA+CA 2.04	0.879
ERCC1 8092 A allele	CC 1.42	0.879
ERCC2 312 G allele	GG + GA 2.04	0.084
ERCC2 312 G allele	AA 1.17	0.084
ERCC2 312 A allele	AA+GA 2.04	0.511
ERCC2 312 A allele	GG 1.42	0.511
ERCC2 751 A allele	AA+AC 1.80	0.287
ERCC2 751 A allele	CC not reached	0.287
ERCC2 751 C allele	CC + AC 3.07	0.181
ERCC2 751 C allele	AA 1.42	0.181

ISSN: 1471-2350